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OBJECTIVES We report our initial experience with percutaneous pulmonary valve replacement in animals
with large pulmonary trunks, using a modified percutaneous approach.
BACKGROUND Percutaneous pulmonary valve replacement has recently been introduced, and early clinical
experience has been reported. This technique is presently limited to patients with a right
ventricular outflow tract no bigger than 22 mm in diameter.
METHODS In seven animals (groups 1 and 3), we implanted a newly designed nitinol stent in the shape
of a conduit with a central restriction of its diameter, containing an 18-mm bovine valve, as
a one-step procedure. The animals in groups 1 and 3 were sacrificed after valve implantation
and after two-month follow-up, respectively. In the second group (n  3), we expected to
percutaneously reduce the diameter of the pulmonary artery. Eight weeks later, we implanted
an 18-mm valve mounted in a balloon-expandable stent. These animals were sacrificed after
valve implantation.
RESULTS Eight of 10 devices were successfully delivered and were functioning perfectly at the initial
evaluation and after two months. We failed to cross the tricuspid valve in two cases. The
downsize mechanism allowed the pulmonary diameter to be reduced from 30 to 18 mm,
without an impact on right ventricular function in any of the animals.
CONCLUSIONS Non-surgical implantation of a pulmonary valve is possible in ewes with all types of
pulmonary trunk, regardless of its size. A “downsize” stent is needed to allow valve
implantation in a large trunk. Further refinements will make this technique feasible in
humans. (J Am Coll Cardiol 2004;43:1082–7) © 2004 by the American College of
Cardiology Foundationm
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intil recently, surgery was the only technique available for
ardiac valve replacement. Percutaneous valve implantation
as first reported in animals and more recently in humans
1–6). The device we developed is a biologic valve harvested
rom the bovine jugular vein mounted in a balloon-
xpandable stent. However, because bovine jugular venous
alves are available up to 22 mm in diameter, indications in
umans are presently limited to patients who have a right
entricular outflow tract (RVOT) that does not exceed that
See page 1088
aximum diameter. Unfortunately, the most common
roups of patients requiring pulmonary valve replacement
re children and adults who underwent transannular patch
epair of tetralogy of Fallot (TOF) during infancy (7–9).
heir pulmonary trunk is often larger in size. The biologic
alves available at present do not reach this size, thus
From the *Service de Cardiologie Pe´diatrique, Hoˆpital Necker Enfants Malades,
aris; †INSERM EMIU 0016, Faculte´ de Necker Enfants Malades, Paris, France;
nd ‡Cardiothoracic Unit, Great Ormond Street Hospital, London, United King-
om. This study was financially supported via grants provided by the Fondation de
’Avenir (Paris, France) and the Fe´de´ration Franc¸aise de Cardiologie (Paris, France).
Manuscript received May 20, 2003; revised manuscript received September 20,r003, accepted October 27, 2003.aking percutaneous implantation technically unfeasible.
oreover, surgical valve implantation in such patients is
sually associated with a size reduction of the RVOT and
he introduction of a biologic valve or homograft. To
roaden the indications of a percutaneous approach to the
hole anatomic spectrum of pulmonary regurgitation, we
eveloped a self-expandable stent that allowed us to down-
ize the diameter of the vessel to the available valve
iameter. Because the deployment of such a stent could be
ampered in a tortuous pulmonary anatomy, we also inves-
igated a two-step approach in which valve implantation was
elayed. We report our experience with these new stents in
wes that have a pulmonary trunk of at least 25 mm in
iameter.
ETHODS
evice preparation for downsizing the diameter of the
ulmonary trunk. We designed and developed a self-
xpandable stent constructed from 0.27-mm nitinol wire in
he shape of a conduit with a central restriction of its
iameter (AMF, Groupe Le´pine, Lyon, France). The over-
ll length of the deployed device was 5.5 cm. The extrem-
ties had a spontaneous diameter of 30 mm, and the central
estricted part had a diameter of 18 mm. The length of this
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March 17, 2004:1082–7 New Insights in Percutaneous Valve Replacementestriction was 15 mm, which is the approximate length of
n 18-mm valve. To guarantee the perfect sealing of this
evice, we sutured a 0.3-mm polytetrafluoroethylene
PTFE) membrane, usually used for covered stent (Zeus
nc., Orangeburg, South Carolina), on the outside of the
elf-expandable nitinol stent with a 7.0-propylene thread
Fig. 1). This covered stent has been tested in vitro, with
ncouraging results (no stent fracture and no disruption of
he PTFE membrane), but data showing long-term dura-
ility are presently missing.
For a subgroup of animals (one-step procedure), a natu-
ally valved venous segment of 18 mm, harvested from the
ovine jugular vein, was mounted into the restricted part of
he self-expandable stent. The extremities of the downsizing
tent were supposed to ensure the fixation of the device
gainst the pulmonary wall. The central part of the stent
nsured the downsizing of the pulmonary artery (PA) and
Abbreviations and Acronyms
PA  pulmonary artery
PTFE  polytetrafluoroethylene
RV  right ventricular
RVOT  right ventricular outflow tract
TOF  tetralogy of Fallot
igure 1. (A) The newly designed stent is shown uncovered. The extrem-
ties have a diameter of 30 mm, whereas the central part is 18 mm. (B) A
olytetrafluoroethylene membrane is covering the stent to ensure sealing ofahe device.cted as a supporting structure for the 18-mm heterograft
Fig. 2).
For the remaining group of animals (two-step procedure),
he self-expandable stent was used non-valved to downsize
he diameter of the vessel for a subsequent valve implanta-
ion with a Numed stent (Numed Inc., Hopkinton, New
ork). This latter device was prepared, as previously de-
cribed, using an 18-mm valved segment sutured into a
alloon-expandable CP stent (Numed Inc.) (1). All devices
ere stored in a glutaraldehyde solution.
elivery systems. We developed a delivery system specif-
cally for this application. It consisted of a front-loading
ong sheath pre-mounted with a balloon-in-balloon catheter
nside, when used to deliver a balloon-expandable stent
Numed Inc.). A balloon was not necessary to deliver the
itinol stent. The distal part of the sheath is larger than the
roximal part, liberating extra space for stent placement.
herefore, the outer size of the delivery system is 18-F
istally when used to implant a valved stent (nitinol or CP
tent) and 16-F when used to deliver the non-valved,
ownsizing nitinol stent. The length of this distal part was
cm for the self-expandable stent as compared with 5 cm
or the balloon-expandable stent. The sheath can freely slide
ver the stent. At the tip of the catheter, a 1-cm-long dilator
as glued to allow a smooth transition between the tip and
he sheath, thus limiting the risk of traumatizing the vessel
t skin insertion.
epartition of animals. Ten ewes weighing 60 to 70 kg
ere included. Animals were divided into three groups
ccording to the type of stent implanted and the length of
ime until sacrifice. In the first (n  3) and third groups
n  4), we intended to implant a 30-mm device sheltering
igure 2. A front view of the stent, showing the valve in the closed
osition, as seen from the ventricular side.n 18-mm valve as a one-step procedure. Animals from
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New Insights in Percutaneous Valve Replacement March 17, 2004:1082–7roups 1 and 3 were sacrificed just after valve implantation
nd after two-month follow-up, respectively. In the second
roup (n  3), we expected to percutaneously reduce the
iameter of the PA to allow for further pulmonary valve
lacement. In this latter group, we intended to implant an
8-mm valve into the previously placed stent 6 to 10 weeks
fter the first procedure. Animals from this group were
acrificed just after valve implantation.
ercutaneous reduction of pulmonary trunk diameter
nd pulmonary valve replacement. All ewes underwent
atheterization for transcatheter implantation of a biologic
alve in the pulmonary position under general anesthesia.
nesthesia was induced with 10 mg/kg of thiopental and
aintained with halothane in mechanically ventilated ewes.
ardiac and respiratory functions were monitored through-
ut the procedure. The right jugular vein was prepared for
atheterization. Heparin (100 IU/kg) was administrated
nce during the procedure. Animals from group 3 received
low dose of aspirin and intramuscular low-molecular-
eight heparin twice daily throughout the two-month
ollow-up. All animals were treated according to the Euro-
ean regulations for animal experimentation (10).
In groups 1 and 3, the valved device was loaded into the
8F delivery system (Numed Inc.) and inserted through the
ight jugular vein over a previously positioned 0.035-inch
0.089-cm), extra-stiff guide wire (Amplatzer, Golden Val-
ey, Minnesota). The device was advanced and deployed in
he pulmonary trunk by simply uncovering the device. By
pplying the native valve to the wall of the vessel, the stent
mpinged on the native valvular function. A balloon was not
eeded for deployment of this device.
In the second group, we aimed to test a stepwise
mplantation. Using the same technique, a non-valved
evice was implanted using a 16-F delivery system. In our
xperience in ewes, pulmonary regurgitation created by the
mplantation of a non-valved stent frequently led to severe
rowth impairments and/or animal death (unpublished
ata). Moreover, because we aimed to test the feasibility of
two-step procedure, failure of the native valve was not
andatory to answer that question. Therefore, the tested
on-valved device was implanted above the native pulmo-
ary valve, which remained functional. Six to 10 weeks later,
he animals were recatheterized to implant a biologic valve.
0.035-inch, extra-stiff wire (Amplatzer) was positioned in
he distal right PA through the previously placed stent.
fter rinsing, the valved stent was crimped down on the
uter balloon of the 18-F delivery system and covered before
ts skin insertion, as previously described (1). The delivery
ystem was loaded onto the guide wire and advanced into
he restricted part of the previously placed stent. The valved
tent was then uncovered and deployed within the restricted
art of the previously placed stent by subsequently inflating
he inner and outer balloons of the delivery system. The
alloons were finally deflated and retrieved with the delivery
ystem, leaving the valved stent in the deployed position.
he valved stent was dilated to match the diameter of the cestricted part of the first stent to the diameter of the
vailable valves (18 mm). Because the RVOT was larger
han 18 mm, the restricted part of the nitinol stent was
andatory to secure the 18-mm valve supported by the
alloon-expandable stent.
ardiac catheterization and testing of implanted device.
ight ventricular (RV) and pulmonary pressures were mea-
ured before and after device implantation to determine the
radient across the stent. Angiographic evaluation consisted
f a pulmonary injection distal to the device and right
entriculography. Angiograms were obtained before the
rocedure to define the anatomy of the pulmonary root and
o measure the size of the pulmonary trunk. Studies were
lso repeated after implantation and before the animals were
acrificed to confirm the appropriate position and sealing of
he stent, as well as to verify the function of the implanted
alve.
raft retrieval. Grafts were explanted just after valve
nsertion in animals from groups 1 and 2 (immediately in
wes from group 1 and 2 months after the initial procedure
n animals from group 2) and two months after valve
mplantation in animals from group 3. Before harvesting,
eparin (300 IU/kg) was intravenously given. The heart and
ungs were retrieved together in one block. The pulmonary
ascular tree was examined to determine the position of the
mplanted device in relation to the pulmonary valve annulus.
he device was then harvested with a section of the PA and
insed to remove excess intraluminal blood. All grafts were
nspected, and the competence of the valve was grossly
ested by passing a fluid over the graft. All lungs were
issected and inspected macroscopically to look for lung
nfarcts.
ESULTS
ne-step pulmonary valve replacement (groups 1 and
). The mean size of the pulmonary trunk was 26 mm. Six
f seven devices were successfully implanted. In one animal,
t was impossible to cross the tricuspid valve. The mean
ystolic transprosthetic gradient was 11 mm Hg (range 8 to
6 mm Hg) (Table 1). This gradient did not significantly
hange when comparing short- and long-term evaluations
11 vs. 11.25 mm Hg). There was no early or late stent
igration. Angiographic evaluation revealed that the im-
lants were in the desired position and confirmed the
ealing of the stent cover, with no leak between the device
nd pulmonary wall. Valves were competent angiographi-
ally and hemodynamically (Fig. 3). No stent fracture was
bserved. At autopsy, valve leaflets were thin and perfectly
obile in the early as well as late implantations. In group 1,
oagulated blood was trapped between the restricted part of
he stent and the vascular wall, so there was an absence of
lood flow in this area. In group 3, where animals were
arvested two months after implantation, all devices were
xed to the pulmonary wall, and nitinol wires were partially
overed by fibrous tissue (Fig. 4). No macroscopic lung
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March 17, 2004:1082–7 New Insights in Percutaneous Valve Replacementnfarcts were found. However, no histologic study was made
o eliminate small lesions. No macroscopic vascular damage
as noted when inspecting the vascular wall along the
evice. As expected, the pulmonary native leaflets were
pplied between the stent and the pulmonary wall, thus
otally inactivating them.
wo-step pulmonary valve replacement (group 2). The
ean size of the pulmonary trunk was 26.3 mm. A diameter
eduction of the pulmonary trunk was possible in all
nimals. The mean systolic transprosthetic gradient was
mm Hg (range 5 to 12 mm Hg). The RV/aortic pressure
atio was 50% in all animals. Angiographic evaluation
onfirmed the perfect position of all implants, without any
eak between the device and pulmonary wall (Fig. 5). All
wes survived the first procedure, but two of three ewes
uccessfully received the valvular implant two months later.
n the remaining animal, despite several attempts, we failed
o cross the tricuspid valve. Indeed, coming from the jugular
ein, the angle between the tricuspid valve and RV outlet
as too narrow to allow for advancement of the device in
he desired position. The competency of the implanted
alves was confirmed at angiographic evaluation and au-
opsy. There was no evidence of stent fracture. The valved
Table 1. Hemodynamic Data
Mean Pressures
(mm Hg) Im
Groups 1 and 3 RVP (S/D/ED)
PAP (S/D)
Group 2 RVP (S/D/ED)
PAP (S/D)
D  diastolic; ED  end-diastolic; NA  not applicable; PA
S  systolic.
igure 3. Angiogram showing the perfect competence of the 18-mm
mplanted valve (equivalent of a lateral view). Note the size of the
ulmonary artery trunk as compared with the size of the restricted arealhere the valve is located.tent was in a good position within the restricted part of the
itinol stent. The external stent was fixed to the PA wall. As
xpected, the native pulmonary valve was not damaged and
hus functioned normally.
ISCUSSION
atients who underwent transannular patch repair of TOF
uring infancy can have pulmonary trunks that often exceed
0 mm in diameter, making percutaneous implantation
echnically impossible with the current approach (1–3,7–9).
e have proposed various solutions to resolve this problem.
irst, it is possible to implant two Numed valved stents—
ne in each PA. However, this solution will be expensive,
ill increase the duration of the procedure, and will not
liminate blood regurgitation from the pulmonary trunk.
ore interestingly, cooperation between surgeons and car-
iac interventionists would permit a stepwise implantation
ithout requiring extracorporeal circulation. Through a
horacotomy, the PA could be banded, allowing for subse-
uent percutaneous implantation of a pulmonary valve.
one of these solutions is fully satisfactory. Therefore,
nvestigations into other valves and/or technologies were
equired in order to make this technique available for this
atient group.
In our previous experience, we used a balloon-expandable
ascular stent. The wires are made of a soft and highly
alleable alloy consisting of platinum and iridium. In our in
itro studies, we found that the current wire design could
nterfere with valve geometry and function when used at
arge diameters. Therefore, we investigated the two-step
eployment strategy, as we have previously reported in our
uccessful aortic valve implantation (4). As in this experi-
nce, we combined a self-expanding nitinol stent with a
alloon-expandable stent. A single stent based solely on the
se of the nitinol technology was also investigated as a
ne-step deployment strategy. We thus designed a self-
xpandable stent with two different diameters. The diameter
f its extremities is slightly larger than the diameter of the
ulmonary trunk to allow for a mechanical fixation to the
all of the vessel. Because only 18-mm valves were available
or this experiment, the middle part of the stent was
alibrated to shelter this valve size. However, with the use of
ther valves, this stent can be manufactured at various
Timing
re
ation
Just After
Implantation
After 2-Month
Follow-Up
6 35/0/8 36/0/6
24/13 25/14
8 33/0/8 NA
24/12
ulmonary artery pressure; RVP  right ventricular pressure;Befo
plant
22/0/
22/12
25/0/
23/10
P  pengths and diameters to encompass all clinical situations.
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New Insights in Percutaneous Valve Replacement March 17, 2004:1082–7In the present study, implantation of these newly de-
igned stents was feasible in eight of 10 ewes (one additional
nimal received an intravascular non-valved reducer). As in
igure 4. Macroscopic views showing a newly designed, valved nitinol ste
itinol wires and the thin valve inside the stent.
igure 5. Lateral view of right ventriculogram showing perfect sealing of
dhe device.ur initial report in 2000, we failed to implant two valved
evices because of the narrow angle between the tricuspid
alve and the RV outlet. In humans, the large size of the
emoral vein allows for a straighter catheter course and
onsequently reduces the risk of technical failure. Thus,
ince 2001, we have attempted and succeeded in replacing
he pulmonary valve in 23 of 24 patients. The use of this
ew device should not be different in terms of the rate of
uccessful delivery.
The implantation of the downsizing stent permitted the
eduction of the pulmonary trunk to the desired diameter,
ith only a slight elevation of RV pressure, similar to the
ne seen with a mechanical prosthesis. This elevation did
ot increase in animals with late-sacrifice time points. A
imilar reduction of diameter by creating an obstruction to
he RVOT could have repercussions on RV function in
atients with a long-standing history of pulmonary regur-
itation. Therefore, we investigated the possibility of pre-
eding with the insertion of a valve by implantation of a
on-valved, downsizing stent. In humans, this setting
ould allow one to verify the absence of an inappropriate
levation in RV pressures before considering a valve im-
lant. In our protocol, we delayed valvular implantation in
he second group to limit the risk of embolization of the
planted two months after implantation. Note the fibrous covering of thent exevice, but this implantation could probably be done during
a
d
S
p
e
s
s
p
h
s
t
p
o
w
c
v
h
d
a
n
s
f
f
e
b
w
s
a
e
t
A
a
i
a
n
t
o
i
H
s
u
m
a
e
q
C
n
W
b
a
d
i
a
t
r
s
A
T
s
n
h
R
S
M
y
R
1
1087JACC Vol. 43, No. 6, 2004 Boudjemline et al.
March 17, 2004:1082–7 New Insights in Percutaneous Valve Replacementsingle procedure after confirming that the reduction in
iameter is well tolerated.
tudy limitations and unanswered questions. First, in the
resent study, only animals with a normal RVOT were
valuated. Because the aneurysmal dilation of the RVOT, as
een in TOF patients, appears late after surgical repair, a
imilar setting was impossible to achieve in animals. In these
atients, deployment of a self-expandable stent would be
ampered. Placement of a downsizing stent in a non-
ymmetrical RVOT might therefore be an issue. Obstruc-
ion in deployment could theoretically be responsible for a
artial deployment, with lengthening of the device and an
verall reduction of diameter. The central part, in particular,
ould have a smaller diameter than expected and could
reate an additional obstruction to flow, interfering with the
alve geometry and function. However, the designed stent
ad an intrinsic radial force that allows for complete
eployment when external forces are limited, as expected in
neurysmal RVOT. Moreover, each part of the stent—
amely, the proximal and distal extremities and the re-
tricted area, even if they are connected—has its proper
orce and can be deployed completely if one among them is
orced. Thus, if a part is incompletely deployed due to an
xternal constraint that is too significant, the two others can
e deployed normally. In practice, only the ends of the stent,
hose diameter borders that of the RVOT, can be con-
trained. However, in patients with tortuous pulmonary
natomy, where incomplete deployment of the device is
xpected, asymmetrical devices with three different diame-
ers for each part of the stent can be manufactured and used.
stepwise approach, as reported here in group 2, would
lso be indicated. In that case, a balloon-expandable stent,
n addition to supporting the valve, would advantageously
dd radial forces, allowing for complete deployment of the
itinol stent.
Another concern is the evolution of the thrombus forma-
ion found between the stent and PA wall as a consequence
f the “no-flow” and blood entrapment. Although not found
n our animal experiment, a risk of thromboembolism exists.
owever, the risk is limited as long as the device is perfectly
ealed. After a short time, the thrombus is organized and
nlikely to migrate. Over a period of time that formation
ight regress, as seen in our experiment and reported in
neurysms of the aorta treated with a covered stent. How-
ver, long-term studies will be necessary to address this
uestion more accurately.onclusions. Herein, we report new insights into pulmo-
ary valve replacement through a transcatheter technique.
e resolved the problem of implantation in a large RVOT
y designing a new stent made of nitinol wires. This device
llows for a size reduction of the pulmonary trunk to a
iameter that permits percutaneous valve replacement dur-
ng the same procedure or two months later. The future
vailability of this device for human application will lead to
he extension of the present indications to transcatheter
eplacement of the pulmonary valve, regardless of the PA
ize.
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